MEF2C and lung carcinoma: For instance, expression of MYOD1 can predict patient survival in lung cancer patients (Jiang et al., 2015) and high expression of MEF2C is associated with poor outcome in acute myeloid leukemia (AML) patients (Laszlo et al., 2015).